ATE535521T1 - Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten - Google Patents

Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten

Info

Publication number
ATE535521T1
ATE535521T1 AT09726601T AT09726601T ATE535521T1 AT E535521 T1 ATE535521 T1 AT E535521T1 AT 09726601 T AT09726601 T AT 09726601T AT 09726601 T AT09726601 T AT 09726601T AT E535521 T1 ATE535521 T1 AT E535521T1
Authority
AT
Austria
Prior art keywords
pyrrolidine
hydroxymethyl
beta
receptor agonists
adrenergic receptor
Prior art date
Application number
AT09726601T
Other languages
English (en)
Inventor
Richard Berger
Lehua Chang
Scott Edmondson
Stephen Goble
Sookhee Ha
Nam Kar
Ihor Kopka
Bing Li
Gregori Morriello
Chris Moyes
Dong-Ming Shen
Liping Wang
Cheng Zhu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE535521T1 publication Critical patent/ATE535521T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT09726601T 2008-04-04 2009-04-02 Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten ATE535521T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306308P 2008-04-04 2008-04-04
US20604309P 2009-01-27 2009-01-27
PCT/US2009/039253 WO2009124167A1 (en) 2008-04-04 2009-04-02 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
ATE535521T1 true ATE535521T1 (de) 2011-12-15

Family

ID=40671093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09726601T ATE535521T1 (de) 2008-04-04 2009-04-02 Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten

Country Status (38)

Country Link
US (3) US8399480B2 (de)
EP (1) EP2276756B9 (de)
JP (3) JP4783867B2 (de)
KR (3) KR20120118086A (de)
CN (2) CN102056917B (de)
AR (1) AR072043A1 (de)
AT (1) ATE535521T1 (de)
AU (1) AU2009231714B2 (de)
BR (1) BRPI0909768B1 (de)
CA (1) CA2719876C (de)
CL (1) CL2009000815A1 (de)
CO (1) CO6331440A2 (de)
CR (2) CR11751A (de)
CY (1) CY1112552T1 (de)
DO (2) DOP2010000294A (de)
EA (1) EA020135B1 (de)
EC (1) ECSP10010518A (de)
ES (1) ES2376278T3 (de)
GE (1) GEP20125666B (de)
HK (1) HK1147099A1 (de)
HN (1) HN2010002030A (de)
HR (1) HRP20120129T2 (de)
IL (1) IL208215A (de)
MA (1) MA32257B1 (de)
ME (1) ME01988B (de)
MX (1) MX2010010929A (de)
NI (1) NI201000164A (de)
NZ (1) NZ588266A (de)
PE (1) PE20091825A1 (de)
PL (1) PL2276756T3 (de)
PT (1) PT2276756E (de)
RS (1) RS52175B (de)
SG (1) SG188883A1 (de)
SI (1) SI2276756T1 (de)
SV (1) SV2010003687A (de)
TW (1) TWI378098B (de)
WO (2) WO2009124166A1 (de)
ZA (1) ZA201006720B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2470012B1 (de) * 2009-08-27 2014-11-05 Merck Sharp & Dohme Corp. Neue, aus einem pyrrolidin abgeleitete beta-3-adrenerge rezeptoragonisten
BR112012007829A2 (pt) * 2009-10-07 2015-09-22 Merck Sharp & Dohme método para tratar bexiga hiperativa, e, composição farmacêutica.
CA2796877A1 (en) * 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CN103140134B (zh) * 2010-07-23 2015-07-29 默沙东公司 新吡咯烷衍生的β3肾上腺素能受体激动剂
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2011285928B9 (en) * 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
GB2484713A (en) 2010-10-21 2012-04-25 Optovate Ltd Illumination apparatus
JP6042433B2 (ja) * 2011-08-11 2016-12-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 1,2,4−トリアゾリル置換されたケトエノール類
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
US9139819B2 (en) 2011-11-18 2015-09-22 Codexis, Inc. Biocatalysts for the preparation of hydroxy substituted carbamates
WO2013119910A1 (en) 2012-02-09 2013-08-15 Altherx, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
JP2015178458A (ja) * 2012-07-25 2015-10-08 杏林製薬株式会社 ベンゼン環縮合含窒素5員複素環式化合物、またはその薬理学的に許容される塩
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis
EP2968269B1 (de) * 2013-03-15 2019-07-10 Merck Sharp & Dohme Corp. Verfahren zur herstellung von beta-3-agonisten und zwischenprodukten davon
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN103760286A (zh) * 2014-01-14 2014-04-30 北京万全德众医药生物技术有限公司 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
RU2712268C2 (ru) * 2015-01-20 2020-01-28 Мерк Шарп И Доум Корп. ИНГИБИТОРЫ ФАКТОРА XIa
IL258856B1 (en) 2015-10-23 2024-03-01 Velicept Therapeutics Inc Zwitterion solvegron and its uses
WO2017210700A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
GB201705365D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
GB201705364D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CA3064989A1 (en) 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
AU2018282105A1 (en) 2017-06-06 2019-12-12 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201718307D0 (en) 2017-11-05 2017-12-20 Optovate Ltd Display apparatus
KR20200103034A (ko) 2017-12-21 2020-09-01 교린 세이야꾸 가부시키 가이샤 야간빈뇨 치료제
GB201800574D0 (en) 2018-01-14 2018-02-28 Optovate Ltd Illumination apparatus
GB201803767D0 (en) 2018-03-09 2018-04-25 Optovate Ltd Illumination apparatus
GB201807747D0 (en) 2018-05-13 2018-06-27 Optovate Ltd Colour micro-LED display apparatus
WO2019224788A1 (en) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
US20220117971A1 (en) * 2018-12-05 2022-04-21 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
CN109503500A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种2-(2-氧代吡嗪-1(2h)-基)乙酸的合成方法
CN109734712B (zh) * 2019-01-30 2020-10-20 广东东阳光药业有限公司 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CN113840607A (zh) 2019-03-18 2021-12-24 尤偌万科学有限公司 维贝格龙治疗膀胱过度活动症的用途
TW202102883A (zh) 2019-07-02 2021-01-16 美商瑞爾D斯帕克有限責任公司 定向顯示設備
CN114616498A (zh) 2019-08-23 2022-06-10 瑞尔D斯帕克有限责任公司 定向照明设备和防窥显示器
EP4028805A4 (de) 2019-09-11 2023-10-18 RealD Spark, LLC Umschaltbare beleuchtungsvorrichtung und sichtschutzanzeige
CN114730044A (zh) 2019-09-11 2022-07-08 瑞尔D斯帕克有限责任公司 定向照明设备和隐私显示器
KR20220077914A (ko) 2019-10-03 2022-06-09 리얼디 스파크, 엘엘씨 수동형 광학 나노구조를 포함하는 조명 장치
KR20220077913A (ko) 2019-10-03 2022-06-09 리얼디 스파크, 엘엘씨 수동형 광학 나노구조를 포함하는 조명 장치
US11287562B2 (en) 2020-02-20 2022-03-29 Reald Spark, Llc Illumination apparatus including mask with plurality of apertures and display apparatus comprising same
TW202239412A (zh) 2020-12-22 2022-10-16 瑞士商優洛凡特科學公司 使用維貝格隆(vibegron)並監測地高辛(digoxin)以治療膀胱過動症的方法
WO2022175848A1 (en) 2021-02-16 2022-08-25 Urovant Sciences Gmbh Methods of treating heart failure with vibegron
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
US20240122958A1 (en) * 2022-10-18 2024-04-18 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
US7750029B2 (en) * 2002-11-07 2010-07-06 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
FR2874011B1 (fr) * 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

Also Published As

Publication number Publication date
ME01988B (me) 2012-08-31
EP2276756B9 (de) 2012-08-15
DOP2013000267A (es) 2014-01-31
KR101331771B1 (ko) 2013-11-22
IL208215A0 (en) 2010-12-30
DOP2010000294A (es) 2010-12-31
CL2009000815A1 (es) 2009-08-21
EA020135B1 (ru) 2014-08-29
CN102391255B (zh) 2014-07-09
JP2011201897A (ja) 2011-10-13
MX2010010929A (es) 2010-11-12
AR072043A1 (es) 2010-08-04
AU2009231714B2 (en) 2011-11-03
JP4783870B1 (ja) 2011-09-28
IL208215A (en) 2014-04-30
US8653260B2 (en) 2014-02-18
AU2009231714A1 (en) 2009-10-08
RS52175B (en) 2012-08-31
EP2276756B8 (de) 2012-04-11
BRPI0909768A2 (pt) 2015-10-06
CA2719876A1 (en) 2009-10-08
ES2376278T3 (es) 2012-03-12
CR11751A (es) 2010-11-22
HRP20120129T8 (en) 2012-04-30
KR101288798B1 (ko) 2013-07-23
BRPI0909768B1 (pt) 2019-01-15
CN102056917A (zh) 2011-05-11
CN102391255A (zh) 2012-03-28
KR20100126860A (ko) 2010-12-02
GEP20125666B (en) 2012-10-10
KR20120104257A (ko) 2012-09-20
ECSP10010518A (es) 2010-11-30
CA2719876C (en) 2013-10-01
JP5432846B2 (ja) 2014-03-05
HN2010002030A (es) 2012-08-13
MA32257B1 (fr) 2011-04-01
CN102056917B (zh) 2014-11-05
TW200944521A (en) 2009-11-01
CR20120282A (es) 2012-07-03
HRP20120129T2 (hr) 2012-09-30
WO2009124166A1 (en) 2009-10-08
JP4783867B2 (ja) 2011-09-28
SV2010003687A (es) 2011-03-23
CO6331440A2 (es) 2011-10-20
US20090253705A1 (en) 2009-10-08
EA201071169A1 (ru) 2011-04-29
CY1112552T1 (el) 2016-02-10
EP2276756A1 (de) 2011-01-26
JP2012020961A (ja) 2012-02-02
PE20091825A1 (es) 2009-12-04
ZA201006720B (en) 2011-05-25
EP2276756B1 (de) 2011-11-30
NI201000164A (es) 2011-06-21
US8399480B2 (en) 2013-03-19
KR20120118086A (ko) 2012-10-25
US20120258963A1 (en) 2012-10-11
US20110028481A1 (en) 2011-02-03
PL2276756T3 (pl) 2012-04-30
PT2276756E (pt) 2012-02-03
WO2009124167A1 (en) 2009-10-08
SI2276756T1 (sl) 2012-04-30
US8247415B2 (en) 2012-08-21
TWI378098B (en) 2012-12-01
HK1147099A1 (en) 2011-07-29
SG188883A1 (en) 2013-04-30
HRP20120129T1 (en) 2012-03-31
JP2011510023A (ja) 2011-03-31
NZ588266A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
ATE535521T1 (de) Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
BRPI0806500A2 (pt) Agonistas gpcr de piperidina
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
ATE531710T1 (de) Piperidin-gpcr-agonisten
BRPI0921242A2 (pt) composições para tratamento bucal para sensibilidade.
BRPI0921815A2 (pt) compostos receptores de apj
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI0919135A2 (pt) compostos inéditos como ligantes do receptor canabinóide.
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
DK2348809T3 (da) Balleindpakningsmaskine
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
DK2132185T3 (da) Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander
BRPI0917563A2 (pt) porta-objeto
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
IT1396886B1 (it) Lavatrice per mezzene
ATE554652T1 (de) Molluskizid
FI20085952L (fi) Kyllästys
FR2927888B1 (fr) >